Metabolic dysfunction-associated steatohepatitis

This small Phase 2 study tested two doses of vonafexor, an oral drug, in 10 people with mild-to-moderate chronic kidney disease and suspected MASH (a type of fatty liver disease). The goal was to see if vonafexor could improve kidney function. However, the trial was terminated ea…

This early-stage study tested an experimental drug called FT-4101 in 14 overweight or obese adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat. The study was stopped early, so results are limited.

This study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …

This study tested a drug called belapectin to see if it could prevent the formation of esophageal varices (enlarged veins in the esophagus) in people with NASH cirrhosis and signs of high blood pressure in the liver. The trial enrolled 357 adults and compared belapectin to a plac…

This study tested a small device worn on the ear that uses mild electrical pulses to help control pain after a liver transplant. The goal was to see if it could reduce the need for strong painkillers like opioids. The study was stopped early and included 27 adults waiting for a l…

This study was designed to collect information about Chinese patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. Researchers planned to track how the disease is diagnosed and treated in real-world clinics, and to understand patients' knowledge and beliefs about …

This early-stage study looked at how the drug amcenestrant is processed in the body of women aged 40-75 with mild or moderate liver problems, compared to women with healthy livers. The goal was to understand dosing and safety. However, the trial was terminated before completion, …